News 7/28/2022 Brookline Capital Acquisition Corp and Apexigen, Inc. Announce Stockholder Approval of Merger 7/18/2022 Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination 6/30/2022 Brookline Capital Acquisition Corp. Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital 5/20/2022 Apexigen Releases May 16th Investor Day Corporate Presentation 5/3/2022 Brookline Capital Acquisition Corp. Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital 4/25/2022 Apexigen to Host Investor Day to Provide an Overview of its Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform on Monday, May 16, 2022 3/18/2022 Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company Link to Company Presentation 1/28/2021 Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering AdvertisementShare this:TwitterFacebookLike this:Like Loading...
Brookline Capital Acquisition Corp